Clinical trials
Phase 4 Peripheral Nervous System Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2015 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Terminated | 3 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Tanta University | 2 |
| Ain Shams University | 1 |
| Boston Scientific Corporation | 1 |
| Eisai Co., Ltd. | 1 |
| Endo USA Inc., a Keenova Therapeutics Company | 1 |
| Gilead Sciences | 1 |
| Groupe Hospitalier Pitie-Salpetriere | 1 |
| Marco Schiuma | 1 |
| Mit Ghamr Oncology Center | 1 |
| NEMA Research, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Nervous System Diseases | 16 |
| Diabetic Neuropathies | 3 |
| Neoplasms | 3 |
| Diabetes Mellitus | 2 |
| Neuralgia | 2 |
| Pain | 2 |
| Polyneuropathies | 2 |
| Bronchiolitis Obliterans Syndrome | 1 |
| Carpal Tunnel Syndrome | 1 |
| Complex Regional Pain Syndromes | 1 |
Trials
Showing 26 to 16 of 16. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.